The price of Akynzeo IV is not publicly disclosed by its manufacturers, Eisai and H. Lundbeck [1]. This information is typically available through private negotiations between pharmaceutical companies and healthcare providers or payers.
What is Akynzeo IV?
Akynzeo IV is an intravenous antiemetic medication used to prevent chemotherapy-induced nausea and vomiting (CINV). It is a combination of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-5-HT3 receptor antagonist [1].
When did Akynzeo IV receive FDA approval?
Akynzeo IV received FDA approval in November 2020 [1].
How does Akynzeo IV work?
Akynzeo IV works by blocking NK1 receptors and 5-HT3 receptors in the brain. These receptors are involved in the pathways that trigger nausea and vomiting during chemotherapy [1].
What are the alternatives to Akynzeo IV for CINV prevention?
Other classes of antiemetic drugs used for CINV prevention include serotonin-5-HT3 receptor antagonists (e.g., ondansetron, granisetron), dopamine antagonists, and corticosteroids [2]. Newer NK1 receptor antagonists are also available in oral formulations [3].
What is the patent status of Akynzeo IV?
Information regarding specific patent expirations for Akynzeo IV is not readily available in public databases and would typically be found through specialized patent tracking services like DrugPatentWatch.com [4].